Mereo BioPharma Group plc
MREO$471M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON36 employees
Drugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
MREO News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
BCT197
Pulmonary Disease, Chronic Obstructive
Prednisone
Chronic Obstructive Pulmonary Disease
Alvelestat oral tablet - dose 1
Alpha 1-Antitrypsin Deficiency
Etigilimab
Solid Tumor, Adult
BGS649
Hypogonadotropic Hypogonadism
Active treatment with a high dose of BGS649
Endometriosis
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
BCT197 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - |
Prednisone | Phase 2 | Chronic Obstructive Pulmonary Disease | - |
Alvelestat oral tablet - dose 1 | Phase 2 | Alpha 1-Antitrypsin Deficiency | - |
Etigilimab | Phase 2 | Solid Tumor, Adult | - |
BGS649 | Phase 2 | Hypogonadotropic Hypogonadism | - |
Active treatment with a high dose of BGS649 | Phase 2 | Endometriosis | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply